share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 27 08:40
Summary by Moomoo AI
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
On February 27, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company, announced in collaboration with Clearmind Medicine Inc., the filing of three new international patent applications. These applications, submitted under the Patent Cooperation Treaty (PCT), cover novel compositions of MDMA, ibogaine, and ketamine, each combined with palmitoylethanolamide (PEA), an active ingredient in SciSparc's CannAmide™. The patents aim to develop therapies for central nervous system disorders and rare diseases. Previously, provisional patents for these compounds were filed with the United States Patent and Trademark Office (USPTO). Additionally, Clearmind has filed eight other USPTO applications and seven PCT applications for various combinations, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. SciSparc specializes in cannabinoid-based pharmaceuticals and is currently working on drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more